Anaptysbio (ANAB) Tax Provisions (2018 - 2026)
Anaptysbio's (ANAB) quarterly Tax Provisions came in at $40000.0 in Q1 2026, down 9.09% YoY from $44000.0 in Q1 2025, and up 107.52% on a QoQ basis from -$532000.0 in Q4 2025.
Powered by 
Analysis
Anaptysbio (ANAB) Tax Provisions (2018 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 6 years of Tax Provisions data on file, last reported at $40000.0 in Q1 2026.
- Quarterly Tax Provisions fell 9.09% year-over-year to $40000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$453000.0 (up 98.51% YoY) and the FY2025 annual result came in at -$449000.0, up 98.53% from the prior year.
- Tax Provisions grew to $40000.0 in Q1 2026, from -$532000.0 in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $44000.0 in Q1 2025 to a low of -$30.5 million in Q4 2024.
- A 4-year average of -$4.4 million and a median of $9000.0 in 2024 frame the typical range for Tax Provisions.
- Annual changes were most pronounced in 2024 — Tax Provisions plunged 762575.0% — and 2025, when it jumped 333.33%.
- Tracing ANAB's Tax Provisions over 4 years: stood at -$4000.0 in 2023, then sank by 762575.0% to -$30.5 million in 2024, then surged by 98.26% to -$532000.0 in 2025, then surged by 107.52% to $40000.0 in 2026.
- The last three Tax Provisions figures came in at $40000.0 (Q1 2026), -$532000.0 (Q4 2025), and $39000.0 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Anaptysbio | 1.63 Bn | 1.34 Bn | - | 40,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 40,000.00 |
| Dec 31, 2025 | -2.83 Mn |
| Jun 30, 2025 | 39,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Dec 31, 2024 | -30.51 Mn |
| Jun 30, 2024 | 9,000.00 |
| Dec 31, 2023 | -34.36 Mn |
| Dec 31, 2019 | -22,000.00 |
| Sep 30, 2019 | -51,000.00 |
| Jun 30, 2019 | -60,000.00 |
| Mar 31, 2019 | -19,000.00 |
| Dec 31, 2018 | -192,000.00 |